Jafari Ali, Mardani Helia, Faghfouri Amir Hossein, AhmadianMoghaddam Minoo, Musazadeh Vali, Alaghi Alireza
Student Research Committee, Department of Community Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
J Health Popul Nutr. 2025 Jul 3;44(1):233. doi: 10.1186/s41043-025-00967-3.
Numerous clinical studies have suggested that cinnamon supplementation may be effective for cardiovascular disease risk factors, but the findings are controversial. This comprehensive systematic review and meta-analysis aimed to assess the impact of cinnamon supplementation on cardiovascular disease risk factors.
Relevant studies were identified through electronic searches of databases, including Web of Science, PubMed, Central, Scopus, and Embase, up to July 2024.
Forty-nine studies were included. Cinnamon supplementation significantly reduced WC (SMD = - 0.40; 95% (CI): - 0.73, - 0.06), DBP (SMD = - 1.04; 95% CI: - 1.54, - 0.55), SBP (SMD = - 0.85; 95% CI: - 1.54, - 0.16), fasting glucose (SMD = - 1.28; 95% CI: - 1.65, - 0.90), fasting insulin (SMD = - 0.26; 95% CI: - 0.50, - 0.02), HbA1c (SMD = - 0.71; 95% CI: - 1.02, - 0.40), HOMA-IR (SMD = - 0.54; 95% CI: - 0.82, - 0.26), postprandial blood glucose (SMD = - 2.28; 95% CI: - 3.48, - 1.08), CRP (SMD = - 0.78; 95% CI: - 1.28, - 0.27), LDL-C (SMD = - 0.71; 95% CI: - 1.02, - 0.40), total cholesterol (TC) (SMD = - 1.15; 95% CI: - 1.55, - 0.75), triglycerides (TG) (SMD = - 0.91; 95% CI: - 1.25, - 0.56), and MDA (SMD = - 0.76; 95% CI: - 1.07, - 0.45). Additionally, cinnamon supplementation significantly elevated HDL-C levels (SMD = 0.56; 95% CI: 0.23, 0.89).
Cinnamon supplementation demonstrated significant benefits in improving cardiovascular risk factors. These findings suggest its potential as an adjunct therapy for improving cardiovascular disease risk factors.
众多临床研究表明,补充肉桂可能对心血管疾病风险因素有效,但研究结果存在争议。本全面的系统评价和荟萃分析旨在评估补充肉桂对心血管疾病风险因素的影响。
通过对数据库进行电子检索来识别相关研究,这些数据库包括科学网、PubMed、CENTRAL、Scopus和Embase,检索截至2024年7月。
纳入了49项研究。补充肉桂显著降低了腰围(标准化均数差[SMD]= -0.40;95%置信区间[CI]:-0.73,-0.06)、舒张压(SMD = -1.04;95% CI:-1.54,-0.55)、收缩压(SMD = -0.85;95% CI:-1.54,-0.16)、空腹血糖(SMD = -1.28;95% CI:-1.65,-0.90)、空腹胰岛素(SMD = -0.26;95% CI:-0.50,-0.02)、糖化血红蛋白(HbA1c)(SMD = -0.71;95% CI:-1.02,-0.40)、稳态模型评估胰岛素抵抗(HOMA-IR)(SMD = -0.54;95% CI:-0.82,-0.26)、餐后血糖(SMD = -2.28;95% CI:-3.48,-1.08)、C反应蛋白(CRP)(SMD = -0.78;95% CI:-1.28,-0.27)、低密度脂蛋白胆固醇(LDL-C)(SMD = -0.71;95% CI:-1.02,-0.40)、总胆固醇(TC)(SMD = -1.15;95% CI:-1.55,-0.75)、甘油三酯(TG)(SMD = -0.91;95% CI:-1.25,-0.56)和丙二醛(MDA)(SMD = -0.76;95% CI:-1.07,-0.45)。此外,补充肉桂显著提高了高密度脂蛋白胆固醇(HDL-C)水平(SMD = 0.56;95% CI:0.23,0.89)。
补充肉桂在改善心血管风险因素方面显示出显著益处。这些发现表明其作为改善心血管疾病风险因素辅助治疗的潜力。